Piasky-Crovalimab-Akkz
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Alhemo-Concizumab-Mtci
Alhemo is a preventive injection for people with hemophilia A or B with inhibitors, aged 12 and above. It helps reduce and prevent bleeding episodes by regulating the clotting pathway.
Datroway-Datopotamab Deruxtecan-Dlnk
Datroway is an antibody-drug conjugate for adults with advanced non-small cell lung cancer that has an EGFR mutation and progressed after standard treatment. It delivers targeted chemotherapy directly to cancer cells to control tumor growth.
Grafapex-Treosulfan
Grafapex is used with fludarabine to prepare adults and children (≥1 year) with AML or MDS for stem cell transplant. It helps replace traditional regimens, offering similar effectiveness with potentially fewer side effects
Journavx-Suzetrigine
Journavx is a non‑opioid oral painkiller approved for adults with moderate‑to‑severe acute pain. It blocks sodium‑channel pain signals in the body, relieving pain without addiction risk.
Gomekli-Mirdametinib
Gomekli treats adults and children (≥2 years) with NF1-related plexiform neurofibromas that can’t be fully removed. It inhibits MEK enzymes to slow tumor growth and reduce tumor size.
Romvimza-Vimseltinib
Romvimza is a tablet for adults with tenosynovial giant cell tumor when surgery might worsen joint function. It blocks CSF-1R to shrink tumors and ease symptoms.
Blujepa-Gepotidacin
Blujepa treats uncomplicated urinary tract infections in females and adolescents with more than 12 years and more than or equal to 40 kg. It’s an oral antibiotic in a new class that combats common UTI bacteria and tackles antibiotic resistance.
Qfitlia-Fitusiran
Qfitlia is a subcutaneous therapy approved for routine prevention of bleeding in patients aged 12 and older with hemophilia A or B, with or without inhibitors. It lowers antithrombin to rebalance clotting and has been shown to reduce annual bleeding rates by around 90%
Vanrafia-Atrasentan
Vanrafia is an oral treatment for adults with primary IgA nephropathy at risk of rapid disease progression. It reduces proteinuria and helps protect kidney function by blocking endothelin A receptors.
